This week, medical technologies company Admedus Limited, headquartered in Australia, announced that it’s reached a very important milestone in the ongoing development of its own patented TAVR project – it has begun animal trials of the device on sheep, and also completed the first successful live implantation of its innovative, single-piece aortic heart valve.
“Today is a significant step for the TAVR project as we move into the next stage of development,” said Admedus CEO Wayne Paterson, who was in the laboratory to observe the first procedure. “It was exciting to observe the first-ever of our unique single-piece valves being placed inside a living heart. These experiments are being conducted by global leaders in the field and will provide critical insight for our Development team as we accelerate towards product commercialisation.”
Admedus focuses on investing in and growing next generation technologies with its partners around the world, while also acquiring strategic assets to keep expanding its product and service offerings and increasing revenues from its current medical sales and distribution business. Its innovative clinical solutions help the healthcare professionals it works with create outcomes for patients that can change their lives for the better.
Admedus previously announced that it would be working with a top European reference laboratory starting this month to conduct a study, called “Experimental assessment of the Admedus valve – ovine model of aortic valve replacement.” The study is a follow-up to the company’s successful lab tests, where several 3D printed valves were run, against a competitor valve as a control, out to 400 million cycles, which equates to roughly 10 years of use in a human heart; the control valve showed major fatigue at 250 million cycles, while the 3D printed Admedus ones were still functional at the end.
This new study will be examining both the feasibility and the safety of the company’s unique, 3D printed, single-piece molded valve in a living subject: sheep. Today marked the first day of the trial period, which will last about five months, as the company implanted its first 3D printed, single-piece valve into a live sheep’s heart. During this period, Admedus will implant valves into multiple sheep before it expands and starts to test the 3D printed valves in a TAVR setting with large calves. By using its proprietary ADAPT technology, which is mostly used in restorative structural heart repair and reconstruction, Admedus will be able to provide the first TAVR – and the only one – that has superior biomechanical control capabilities and a proven resistance to calcification.
The company already has several patent applications currently pending in the US regarding its TAVR device. But this new sheep study is an important step on the road for Admedus’s strategic R&D valve project as it slowly works toward developing valves that can be used in humans.
Discuss this story, and other 3D printing topics, at 3DPrintBoard.com, or share your thoughts below.
You May Also Like
Bowman’s 3D-Printed Parts Set Stage for Industrialization
Bowman International is a small-to-medium-sized enterprise (SME) based in the U.K. that does something seemingly invisible, but crucial in the manufacturing industry and, well, throughout industrialized society. It makes bearings....
3D Printing News Briefs: February 7, 2020
In today’s 3D Printing News Briefs, ASTM International is developing a new AM standard, and 3D4Makers is launching a Luvocom PEKK filament. INMETRO has partnered with Farcco to raise awareness...
HP and NTU Singapore Officially Open Joint Corporate 3D Printing Lab
This week, Nanyang Technological University (NTU) in Singapore officially opened the doors to a new corporate lab that will help manufacturing companies as they work towards adopting digital technology. This...
3D Printing News Briefs: January 22, 2020
In today’s 3D Printing News Briefs, we’ve got a 2019 recap, a new 3D printing conference, a new 3D printer, and a 3D printed medicine story. Prusa is sharing how...
View our broad assortment of in house and third party products.